ARE:NYE-Alexandria Real Estate Equities Inc (USD)

COMMON STOCK | REIT - Office |

Last Closing

USD 99.44

Change

+0.53 (+0.54)%

Market Cap

USD 18.15B

Volume

0.43M

Analyst Target

USD 187.94
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. Alexandria has a total market capitalization of $34.4 billion and an asset base in North America of 74.1 million SF as of March 31, 2024, which includes 42.2 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction and one committed near-term project expected to commence construction in the next two years, 2.5 million RSF of priority anticipated development and redevelopment projects, and 24.1 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for REIT - Office

Symbol Name Price(Change) Market Cap
VNO-PM Vornado Realty Trust

-0.05 (-0.29%)

USD 9.68B
VNO-PL Vornado Realty Trust

-0.04 (-0.23%)

USD 9.63B
VNO Vornado Realty Trust

+0.37 (+0.88%)

USD 8.31B
SLG-PI SL Green Realty Corp

-0.08 (-0.33%)

USD 6.97B
KRC Kilroy Realty Corp

+1.11 (+2.72%)

USD 4.83B
DEI Douglas Emmett Inc

+0.41 (+2.23%)

USD 3.87B
CDP COPT Defense Properties

+0.26 (+0.84%)

USD 3.77B
EQC-PD Equity Commonwealth

N/A

USD 3.72B
OGCP Empire State Realty OP LP

+0.23 (+2.40%)

USD 2.72B
JBGS JBG SMITH Properties

+0.22 (+1.43%)

USD 1.38B

ETFs Containing ARE

GBLD Invesco MSCI Green Buildi.. 6.11 % 0.00 %

+0.11 (+0.00%)

USD 6.69M
RITA ETF Series Solutions - ET.. 5.79 % 0.00 %

+0.12 (+0.00%)

USD 6.98M
DXSI:XETRA Xtrackers - Stoxx Europe .. 5.77 % 0.00 %

N/A

USD 0.02B
HAL:CA Global X Active Canadian .. 4.52 % 0.78 %

+0.20 (+0.00%)

CAD 0.12B
WTRE:XETRA WisdomTree New Economy Re.. 4.51 % 0.00 %

N/A

USD 2.55M
WTER:XETRA WisdomTree New Economy Re.. 4.51 % 0.00 %

N/A

USD 3.98M
WNER:LSE WisdomTree New Economy Re.. 4.51 % 0.00 %

+0.14 (+0.00%)

USD 0.80M
WTNR:LSE WisdomTree New Economy Re.. 4.51 % 0.00 %

+8.90 (+0.00%)

USD 3.28M
WTRE WisdomTree New Economy Re.. 4.44 % 0.00 %

+0.06 (+0.00%)

USD 0.02B
REZ iShares Residential and M.. 4.05 % 0.48 %

+0.66 (+0.00%)

USD 1.07B
JPRE JPMorgan Realty Income ET.. 3.97 % 0.00 %

-0.08 (0.00%)

USD 0.38B
WNEW:LSE WisdomTree New Economy Re.. 3.70 % 0.00 %

+7.90 (+0.00%)

N/A
WTRE:LSE WisdomTree New Economy Re.. 3.70 % 0.00 %

+0.13 (+0.00%)

N/A
PPTY U.S. Diversified Real Est.. 3.32 % 0.53 %

+0.24 (+0.00%)

USD 0.08B
CDZ:CA iShares S&P/TSX Canadian .. 3.18 % 0.66 %

+0.08 (+0.00%)

CAD 0.98B
RENT:AU 3.18 % 0.00 %

N/A

N/A
URNG:LSE Global X Uranium UCITS ET.. 3.02 % 0.00 %

+0.04 (+0.00%)

USD 0.18B
URNU:SW Global X Uranium UCITS ET.. 2.90 % 0.00 %

N/A

USD 0.17B
ZIN:CA BMO S&P/TSX Equal Weight .. 2.90 % 0.59 %

+0.26 (+0.00%)

CAD 0.04B
CSYZ:F Credit Suisse Index Fund .. 2.83 % 0.00 %

N/A

USD 0.13B
GREIT:SW UBS (Irl) ETF plc - FTSE .. 2.83 % 0.00 %

N/A

USD 0.18B
URNU:XETRA Global X Uranium UCITS ET.. 2.50 % 0.00 %

N/A

USD 0.18B
ASRM:XETRA BNP Paribas Easy FTSE EPR.. 1.73 % 0.00 %

-8.00 (0.00%)

N/A
URA Global X Uranium ETF 0.00 % 0.72 %

-0.18 (0.00%)

USD 3.37B
HGR:CA Harvest Global REIT Leade.. 0.00 % 2.68 %

+0.03 (+0.00%)

CAD 0.05B
1659:TSE iShares US REIT ETF 0.00 % 0.00 %

N/A

USD 10.28B
CGRE:CA CI Global REIT Private Po.. 0.00 % 0.00 %

+0.32 (+0.00%)

CAD 0.06B
CSYZ:XETRA UBS (Irl) ETF plc - FTSE .. 0.00 % 0.00 %

N/A

USD 0.22B

Market Performance

  Market Performance vs. Industry/Classification (REIT - Office) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.56% 19% F 11% F
Dividend Return 4.08% 27% F 58% F
Total Return -17.48% 19% F 12% F
Trailing 12 Months  
Capital Gain -22.98% 19% F 11% F
Dividend Return 4.99% 31% F 65% D
Total Return -17.99% 19% F 12% F
Trailing 5 Years  
Capital Gain -37.86% 50% F 15% F
Dividend Return 15.37% 46% F 51% F
Total Return -22.49% 62% D 15% F
Average Annual (5 Year Horizon)  
Capital Gain -4.95% 47% F 12% F
Dividend Return -2.03% 41% F 13% F
Total Return 2.92% 23% F 63% D
Risk Return Profile  
Volatility (Standard Deviation) 20.61% 66% D+ 53% F
Risk Adjusted Return -9.86% 41% F 15% F
Market Capitalization 18.15B 100% F 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.